LOGIN  |  REGISTER
Recursion

List of Medical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 128.80
-0.10 -0.08
1.34M
1.74B
US$ 224.110B
US$ 589.65
-1.18 -0.20
470,793
375.71M
US$ 221.540B
US$ 571.16
-2.32 -0.40
230,472
354.50M
US$ 202.480B
US$ 226.23
-0.56 -0.25
1.20M
706.35M
US$ 159.790B
US$ 101.57
-0.01 -0.01
1.32M
1.48B
US$ 150.320B
US$ 373.12
1.94 0.52
337,921
382.42M
US$ 142.690B
US$ 104.07
-1.27 -1.21
1.97M
1.28B
US$ 133.200B
US$ 860.94
-20.18 -2.29
195,351
123.43M
US$ 106.270B
US$ 739.14
-13.74 -1.82
222,215
79.85M
US$ 59.020B
US$ 192.65
-1.37 -0.71
660,020
286.63M
US$ 55.220B
US$ 210.74
-1.52 -0.72
330,327
237.60M
US$ 50.070B
US$ 86.14
-0.53 -0.61
750,851
580.30M
US$ 49.990B
US$ 151.06
-2.44 -1.59
498,615
283.50M
US$ 42.830B
US$ 230.27
0.26 0.11
212,690
170.30M
US$ 39.210B
US$ 79.42
0.11 0.14
408,333
491.20M
US$ 39.010B
US$ 253.12
-2.71 -1.06
368,722
145.97M
US$ 36.950B
US$ 238.28
-0.53 -0.22
176,791
138.01M
US$ 32.880B
US$ 1.00
-0.33 -0.02
14,013
20.43M
US$ 30.160B
US$ 264.95
-1.33 -0.50
108,075
98.15M
US$ 26.000B
US$ 63.64
0.17 0.27
1.17M
390.02M
US$ 24.820B
US$ 402.03
-1.39 -0.34
87,787
59.53M
US$ 23.930B
US$ 272.58
3.80 1.41
187,706
82.90M
US$ 22.600B
US$ 317.44
-9.75 -2.98
117,883
70.35M
US$ 22.330B
US$ 187.59
-1.59 -0.84
128,041
111.24M
US$ 20.870B
US$ 278.48
1.23 0.44
84,683
71.94M
US$ 20.030B
US$ 129.66
-1.79 -1.36
398,352
152.80M
US$ 19.810B
US$ 101.33
0.04 0.04
3.49M
189.77M
US$ 19.230B
US$ 96.91
-0.61 -0.63
460,730
198.18M
US$ 19.210B
US$ 595.65
3.19 0.54
50,233
28.17M
US$ 16.780B
US$ 75.00
0.03 0.04
365,916
222.91M
US$ 16.720B
US$ 78.30
0.37 0.47
741,230
198.81M
US$ 15.570B
US$ 183.46
-1.54 -0.83
376,446
76.36M
US$ 14.010B
US$ 32.86
-0.42 -1.26
151,390
423.90M
US$ 13.930B
US$ 106.53
-1.89 -1.74
264,316
129.87M
US$ 13.840B
US$ 76.33
-1.60 -2.05
1.17M
172.86M
US$ 13.190B
US$ 103.88
-0.53 -0.51
211,823
113.38M
US$ 11.780B
US$ 298.02
4.84 1.65
79,718
39.16M
US$ 11.670B
US$ 47.66
-0.09 -0.19
222,402
216.84M
US$ 10.330B
US$ 91.48
0.43 0.47
346,004
111.41M
US$ 10.190B
US$ 19.12
0.38 2.03
2.50M
514.06M
US$ 9.830B
US$ 168.25
-2.78 -1.63
131,646
56.29M
US$ 9.470B
US$ 180.34
2.20 1.23
120,435
49.22M
US$ 8.880B
US$ 143.62
1.19 0.84
87,429
53.71M
US$ 7.710B
US$ 48.15
-0.66 -1.35
676,179
151.94M
US$ 7.320B
US$ 323.43
-1.43 -0.44
15,336
21.91M
US$ 7.090B
US$ 82.21
-0.58 -0.70
181,664
77.15M
US$ 6.340B
US$ 105.98
-0.31 -0.29
93,941
57.43M
US$ 6.090B
US$ 185.05
-2.97 -1.58
32,780
32.22M
US$ 5.960B
US$ 16.55
0.36 2.22
54,716
354.19M
US$ 5.860B
US$ 87.16
0.56 0.65
64,141
59.29M
US$ 5.170B
US$ 150.40
4.09 2.80
336,622
34.17M
US$ 5.140B
US$ 116.32
1.90 1.66
119,102
44.19M
US$ 5.140B
US$ 17.45
-0.03 -0.17
602,153
284.09M
US$ 4.960B
US$ 79.97
0.00 0.00
0
58.56M
US$ 4.680B
US$ 100.99
-9.40 -8.52
441,340
38.98M
US$ 3.940B
US$ 58.93
0.05 0.08
162,207
66.31M
US$ 3.910B
US$ 81.34
-0.02 -0.02
113,150
46.81M
US$ 3.810B
US$ 126.75
2.34 1.88
237,348
29.06M
US$ 3.680B
US$ 147.81
-0.63 -0.42
22,192
24.69M
US$ 3.650B
US$ 70.98
0.00 0.00
0
51.11M
US$ 3.630B
US$ 63.81
0.00 0.00
88,596
54.61M
US$ 3.480B
US$ 22.22
-0.33 -1.46
393,962
148.55M
US$ 3.300B
US$ 60.01
0.46 0.77
128,797
48.08M
US$ 2.890B
US$ 72.82
0.64 0.89
103,611
35.04M
US$ 2.550B
US$ 46.14
-0.52 -1.11
100,411
47.37M
US$ 2.190B
US$ 19.42
-0.39 -1.97
671,628
105.73M
US$ 2.050B
US$ 68.26
-1.03 -1.49
51,047
29.06M
US$ 1.980B
US$ 30.84
-1.17 -3.66
346,699
61.15M
US$ 1.890B
US$ 82.93
-0.03 -0.04
28,559
22.69M
US$ 1.880B
US$ 26.76
-0.59 -2.16
117,822
67.93M
US$ 1.820B
US$ 35.46
-0.66 -1.83
137,192
49.72M
US$ 1.760B
US$ 31.00
-0.68 -2.15
287,891
55.88M
US$ 1.730B
US$ 35.17
-0.40 -1.12
94,015
45.86M
US$ 1.610B
US$ 11.90
-0.21 -1.74
314,445
129.39M
US$ 1.540B
US$ 44.75
1.33 3.06
130,185
30.97M
US$ 1.390B
US$ 20.24
-0.77 -3.66
724,855
67.80M
US$ 1.370B
US$ 11.95
-0.87 -6.79
610,112
111.98M
US$ 1.340B
US$ 6.10
0.12 2.01
354,071
217.30M
US$ 1.330B
US$ 9.75
0.09 0.93
262,727
135.42M
US$ 1.320B
US$ 28.40
-0.25 -0.87
124,449
46.12M
US$ 1.310B
US$ 26.04
-0.50 -1.88
76,274
49.37M
US$ 1.290B
US$ 25.79
-0.71 -2.68
38,742
48.15M
US$ 1.240B
US$ 92.52
-0.70 -0.75
8,525
12.72M
US$ 1.180B
US$ 39.50
-0.46 -1.15
43,278
29.19M
US$ 1.150B
US$ 22.80
-0.56 -2.40
37,900
49.71M
US$ 1.130B
US$ 13.09
0.00 0.00
0
83.72M
US$ 1.100B
US$ 13.15
0.03 0.23
100,898
77.89M
US$ 1.020B
US$ 1.32
-0.05 -3.31
516,888
767.70M
US$ 1.010B
US$ 6.75
-0.13 -1.89
112,713
148.10M
US$ 999.680M
US$ 13.45
-0.24 -1.75
29,037
67.77M
US$ 911.170M
US$ 17.54
-0.33 -1.85
66,203
51.43M
US$ 902.080M
US$ 14.24
-0.02 -0.14
109,442
63.21M
US$ 899.790M
US$ 28.71
-0.87 -2.94
44,133
30.91M
US$ 887.430M
US$ 19.25
-0.21 -1.08
62,532
43.39M
US$ 835.260M
US$ 13.04
1.16 9.76
5,519
55.90M
US$ 728.940M
US$ 5.43
-0.22 -3.89
281,829
127.86M
US$ 694.280M
US$ 2.27
-0.06 -2.37
2.78M
301.91M
US$ 683.830M
US$ 7.19
-0.45 -5.90
113,146
93.21M
US$ 669.710M
US$ 2.86
-0.25 -7.90
1.91M
226.18M
US$ 645.740M
US$ 16.18
0.09 0.56
15,061
39.60M
US$ 640.530M
US$ 42.98
0.00 0.00
0
14.30M
US$ 614.610M
US$ 16.76
-0.21 -1.24
108,108
35.82M
US$ 600.340M
US$ 25.61
-0.10 -0.39
48,910
22.34M
US$ 572.130M
US$ 1.49
-0.02 -1.00
977,670
384.57M
US$ 571.090M
US$ 11.72
-0.02 -0.17
237,130
46.42M
US$ 544.040M
US$ 16.14
-0.22 -1.34
47,036
33.31M
US$ 537.620M
US$ 18.99
0.00 0.00
0
28.21M
US$ 535.710M
US$ 12.59
0.19 1.53
97,951
41.20M
US$ 518.500M
US$ 7.64
0.05 0.66
54,918
66.98M
US$ 511.730M
US$ 5.32
-0.23 -4.14
157,248
96.02M
US$ 511.020M
US$ 11.75
0.32 2.80
153,879
41.12M
US$ 482.950M
US$ 15.23
-0.21 -1.36
8,403
31.66M
US$ 482.090M
US$ 11.56
-0.01 -0.09
50,994
41.69M
US$ 481.940M
US$ 18.28
-0.21 -1.14
17,658
25.08M
US$ 458.340M
US$ 8.39
0.03 0.36
46,689
52.87M
US$ 443.310M
US$ 16.87
-0.12 -0.71
7,930
22.66M
US$ 382.270M
C$ 1.30
-0.03 -2.26
20,506
289.14M
C$ 375.880M
US$ 13.19
0.03 0.23
70,714
27.58M
US$ 363.860M
C$ 2.24
0.00 0.00
0
154.17M
C$ 345.340M
US$ 9.63
-0.07 -0.72
82,540
35.31M
US$ 340.040M
US$ 6.77
-0.10 -1.46
91,576
49.96M
US$ 338.230M
US$ 17.17
-0.32 -1.83
31,488
19.56M
US$ 335.850M
US$ 6.95
-0.31 -4.27
242,717
46.71M
US$ 324.630M
US$ 19.96
-1.76 -8.10
105,820
15.16M
US$ 302.590M
US$ 4.14
-0.35 -7.70
950,733
65.38M
US$ 270.350M
US$ 5.80
-0.12 -2.03
92,051
46.32M
US$ 268.660M
US$ 6.93
0.02 0.29
55,008
38.02M
US$ 263.400M
US$ 1.33
-0.08 -5.67
1.52M
195.55M
US$ 260.080M
US$ 9.72
-0.09 -0.92
29,859
26.21M
US$ 254.760M
US$ 6.11
-0.07 -1.13
104,347
40.86M
US$ 249.650M
US$ 6.00
0.00 0.00
0
40.63M
US$ 243.780M
US$ 28.00
0.00 0.00
0
8.53M
US$ 238.840M
US$ 27.37
0.59 2.20
11,336
8.34M
US$ 228.220M
US$ 2.40
-0.06 -2.44
94,459
93.32M
US$ 223.970M
US$ 6.09
-0.26 -4.09
56,995
36.19M
US$ 220.400M
US$ 5.84
0.00 0.00
0
37.47M
US$ 218.820M
US$ 14.10
-0.90 -6.00
103,018
15.25M
US$ 214.950M
US$ 2.71
-0.02 -0.55
370,469
77.35M
US$ 209.230M
US$ 4.71
-0.09 -1.88
99,595
43.03M
US$ 202.670M
US$ 22.33
0.74 3.43
21,193
9.03M
US$ 201.640M
US$ 7.07
-0.01 -0.14
17,496
27.15M
US$ 191.950M
US$ 6.32
-0.28 -4.24
5,751
30.19M
US$ 190.800M
US$ 2.96
-0.03 -0.84
173,005
63.72M
US$ 188.290M
US$ 9.21
-0.07 -0.75
38,267
20.34M
US$ 187.230M
US$ 20.24
-0.68 -3.25
6,089
8.94M
US$ 180.920M
US$ 3.65
-0.05 -1.22
18,907
49.50M
US$ 180.430M
US$ 56.35
0.00 0.00
0
3.20M
US$ 180.320M
US$ 1.67
-0.10 -5.40
112,429
106.67M
US$ 177.610M
US$ 2.41
0.03 1.05
74,532
71.73M
US$ 172.510M
US$ 7.55
-0.35 -4.43
125,354
22.66M
US$ 171.080M
US$ 4.05
-0.05 -1.22
23,672
41.20M
US$ 166.860M
US$ 4.19
0.00 0.00
7,048
39.82M
US$ 166.850M
US$ 2.20
-0.16 -6.60
553,763
74.34M
US$ 163.180M
US$ 3.96
-0.05 -1.25
18,070
41.01M
US$ 162.400M
US$ 2.30
-0.12 -5.00
2.30M
67.16M
US$ 154.400M
US$ 1.06
-0.005 -0.47
202,717
131.10M
US$ 138.310M
US$ 3.32
-0.02 -0.45
5,324
37.63M
US$ 124.740M
US$ 37.55
1.11 3.05
1,612
3.26M
US$ 122.400M
US$ 10.18
0.00 0.00
0
11.94M
US$ 121.550M
US$ 1.06
-0.02 -1.85
123,629
113.34M
US$ 120.140M
US$ 3.58
-0.13 -3.38
99,568
30.49M
US$ 109.000M
US$ 2.39
-0.06 -2.25
38,051
43.44M
US$ 103.600M
US$ 1.45
-0.05 -3.02
1.04M
68.49M
US$ 98.970M
US$ 1.34
-0.03 -1.84
11,681
72.95M
US$ 97.390M
US$ 3.12
-0.11 -3.53
32,801
28.23M
US$ 87.960M
US$ 2.34
-0.06 -2.50
3,846
37.39M
US$ 87.490M
US$ 13.93
-0.10 -0.71
35,923
6.17M
US$ 85.950M
US$ 8.49
0.99 13.20
2,143
10.07M
US$ 85.490M
US$ 2.56
-0.03 -1.16
5,309
33.03M
US$ 84.560M
US$ 2.00
0.02 0.76
29,970
42.37M
US$ 84.530M
US$ 1.02
-0.05 -4.67
348,311
82.11M
US$ 83.750M
US$ 0.59
0.0027 0.46
23,116
140.00M
US$ 83.020M
C$ 0.66
-0.01 -1.49
2,500
125.75M
C$ 83.000M
US$ 11.99
0.05 0.42
1,784
6.77M
US$ 81.170M
US$ 4.38
-0.18 -3.95
68,762
18.15M
US$ 79.500M
C$ 0.64
-0.01 -1.54
52,000
121.18M
C$ 77.560M
US$ 1.64
0.02 0.93
306,234
41.25M
US$ 67.440M
US$ 4.07
-0.13 -2.98
14,369
16.43M
US$ 66.790M
US$ 3.54
0.00 0.00
0
18.60M
US$ 65.840M
US$ 1.29
0.00 0.00
0
49.95M
US$ 64.440M
US$ 7.91
-0.37 -4.47
21,114
7.96M
US$ 62.960M
US$ 5.17
0.29 5.94
23,173
10.63M
US$ 54.960M
US$ 0.93
-0.08 -8.02
1.12M
58.48M
US$ 54.330M
US$ 0.83
0.02 2.32
26,734
62.80M
US$ 52.120M
US$ 20.01
0.00 0.00
0
2.54M
US$ 50.830M
US$ 1.14
-0.01 -0.87
427,348
44.53M
US$ 50.760M
US$ 0.71
-0.0078 -1.08
49,519
68.96M
US$ 49.240M
C$ 0.46
0.06 13.75
79,300
105.09M
C$ 47.820M
US$ 1.52
-0.09 -5.59
146,584
30.69M
US$ 46.650M
US$ 23.69
-0.64 -2.63
7,570
1.75M
US$ 41.450M
US$ 1.33
0.07 5.56
3.56M
30.39M
US$ 40.420M
C$ 0.16
0.00 0.00
21,100
257.06M
C$ 39.840M
US$ 0.25
-0.001 -0.40
206,511
156.55M
US$ 39.290M
US$ 4.86
-0.19 -3.74
5,646
8.00M
US$ 38.890M
US$ 1.13
-0.02 -1.74
10,750
33.58M
US$ 37.950M
US$ 0.31
-0.01 -4.26
678,158
122.80M
US$ 37.820M
US$ 0.94
0.05 5.39
210,327
38.44M
US$ 36.060M
US$ 0.79
0.03 4.34
1.34M
44.58M
US$ 35.400M
US$ 1.12
0.03 2.75
96,009
30.81M
US$ 34.510M
US$ 0.69
-0.0048 -0.69
7,785
50.00M
US$ 34.500M
US$ 0.07
0.00 0.00
34,046
454.66M
US$ 31.830M
US$ 2.04
0.00 0.00
0
15.37M
US$ 31.350M
US$ 0.88
-0.05 -5.25
108,422
34.36M
US$ 30.130M
US$ 0.42
0.03 6.77
241,417
63.60M
US$ 26.780M
US$ 0.66
0.05 7.84
69,412
40.35M
US$ 26.630M
US$ 0.83
-0.001 -0.12
6,419
29.94M
US$ 24.760M
US$ 0.71
-0.06 -7.53
14.85M
34.44M
US$ 24.520M
US$ 0.30
-0.01 -4.46
130,130
78.63M
US$ 23.590M
US$ 0.81
-0.03 -3.24
104,059
28.79M
US$ 23.380M
C$ 0.34
0.01 3.03
4,610
66.61M
C$ 22.650M
US$ 0.35
-0.02 -4.48
957,795
60.89M
US$ 21.560M
US$ 5.91
-0.10 -1.66
2,068
3.50M
US$ 20.680M
C$ 0.27
-0.01 -3.64
4,519
78.05M
C$ 20.680M
C$ 0.19
-0.005 -2.63
5,500
111.36M
C$ 20.600M
C$ 0.18
0.005 2.94
500
114.82M
C$ 20.090M
US$ 1.02
-0.03 -2.86
20,062
18.63M
US$ 19.000M
US$ 1.00
-0.08 -7.31
74,015
18.65M
US$ 18.670M
US$ 1.50
-0.02 -1.32
36,025
12.26M
US$ 18.390M
US$ 1.79
-0.06 -3.24
108,604
9.68M
US$ 17.330M
C$ 0.06
0.00 0.00
0
301.79M
C$ 16.600M
US$ 0.96
0.00 0.00
31,483
17.19M
US$ 16.500M
US$ 0.31
0.00 0.00
0
52.24M
US$ 16.390M
US$ 2.18
-0.08 -3.54
20,993
7.50M
US$ 16.350M
US$ 2.77
-0.24 -7.97
34,524
5.89M
US$ 16.320M
C$ 0.05
0.00 0.00
0
320.55M
C$ 16.030M
US$ 2.67
0.00 0.00
0
5.89M
US$ 15.730M
US$ 2.04
0.00 0.00
0
7.09M
US$ 14.440M
C$ 0.09
-0.005 -5.56
297,700
166.73M
C$ 14.170M
US$ 1.74
-0.06 -3.33
13,591
8.14M
US$ 14.160M
US$ 0.45
-0.03 -6.25
7,000
27.80M
US$ 12.510M
US$ 4.70
-0.03 -0.63
3,798
2.62M
US$ 12.310M
US$ 0.61
0.00 0.00
0
19.72M
US$ 11.960M
US$ 0.32
0.0004 0.13
1.13M
34.10M
US$ 10.810M
US$ 1.29
-0.06 -4.44
30,411
8.01M
US$ 10.330M
US$ 0.36
-0.0069 -1.87
112,717
27.64M
US$ 10.010M
US$ 1.10
-0.03 -2.65
11,364
8.61M
US$ 9.470M
US$ 1.61
0.00 0.00
0
5.85M
US$ 9.420M
US$ 0.60
0.02 2.96
187,806
15.70M
US$ 9.400M
US$ 4.58
0.00 0.00
0
2.04M
US$ 9.340M
C$ 0.04
0.00 0.00
1.26M
227.04M
C$ 9.080M
US$ 5.70
-0.21 -3.55
3,381
1.50M
US$ 8.550M
US$ 0.41
0.03 6.65
365,687
20.22M
US$ 8.270M
US$ 1.45
-0.05 -3.33
13,781
5.68M
US$ 8.240M
US$ 2.67
-0.01 -0.37
13,104
3.07M
US$ 8.200M
US$ 9.56
6.45 207.40
17,714
799,966
US$ 7.650M
US$ 5.62
0.00 0.00
0
1.29M
US$ 7.250M
US$ 1.01
-0.06 -5.61
87,631
6.89M
US$ 6.960M
US$ 2.34
-0.03 -1.27
22,089
2.95M
US$ 6.900M
US$ 1.44
-0.06 -4.00
20,790
4.50M
US$ 6.480M
US$ 6.67
0.58 9.47
428,597
959,988
US$ 6.400M
US$ 0.67
0.0059 0.89
11,889
9.45M
US$ 6.290M
US$ 1.12
0.04 3.43
55,415
5.41M
US$ 6.040M
C$ 0.06
0.00 0.00
0
96.48M
C$ 5.790M
US$ 2.39
0.00 0.00
0
2.39M
US$ 5.710M
C$ 0.05
0.00 0.00
0
101.29M
C$ 5.060M
C$ 0.05
0.00 0.00
5,000
100.43M
C$ 5.020M
US$ 0.05
0.0005 1.03
10,000
97.85M
US$ 4.790M
US$ 0.06
0.00 0.00
0
73.90M
US$ 4.510M
US$ 4.00
-0.13 -3.15
6,236
1.09M
US$ 4.360M
US$ 0.41
-0.0091 -2.17
211,603
9.77M
US$ 4.020M
US$ 0.78
0.00 0.00
0
4.85M
US$ 3.780M
US$ 1.90
-0.09 -4.29
12,934
1.86M
US$ 3.520M
US$ 2.10
-0.02 -1.08
2,422
1.67M
US$ 3.500M
US$ 0.31
-0.04 -12.57
4,150
11.28M
US$ 3.450M
US$ 4.36
-0.08 -1.80
1,094
761,318
US$ 3.320M
US$ 1.81
-0.01 -0.55
13,681
1.70M
US$ 3.080M
US$ 1.57
0.07 4.67
3,148
1.80M
US$ 2.830M
C$ 0.05
-0.005 -10.00
104,485
58.00M
C$ 2.610M
US$ 0.15
0.00 0.00
0
16.88M
US$ 2.530M
US$ 1.31
0.01 0.77
174,611
1.81M
US$ 2.370M
US$ 2.51
0.07 2.87
2,921
902,665
US$ 2.270M
C$ 0.07
0.00 0.00
0
22.82M
C$ 1.600M
US$ 0.47
0.00 0.00
0
3.20M
US$ 1.520M
US$ 0.08
0.00 0.00
0
16.67M
US$ 1.370M
US$ 0.20
0.00 0.00
0
5.24M
US$ 1.060M
US$ 0.03
0.00 0.00
0
25.29M
US$ 860K
US$ 0.04
0.00 0.00
0
16.00M
US$ 640K
US$ 0.01
0.00 0.00
0
28.05M
US$ 337K
C$ 0.005
0.00 0.00
0
59.81M
C$ 299K
US$ 0.25
0.00 0.00
0
427,401
US$ 107K
US$ 0.001
0.00 0.00
0
29.91M
US$ 30K
US$ 0.01
0.00 0.00
0
1.78M
US$ 21K
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 1.60
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
C$ 0.54
0.00 0.00
0
-
C$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest News From Medical Stocks


Agilent Technologies Announces 21 CFR Part 11 Compliance Software for xCELLigence RTCA eSight

SANTA CLARA, Calif. / Dec 01, 2025 / Business Wire / Agilent Technologies Inc (NYSE: A) today announced the release of a new 21 CFR Part 11 compliance software for the Agilent xCELLigence Real-Time Cell Analysis (RTCA) eSight system. The software includes a compliance license and enhanced security features, allowing this multiplex live-cell analysis system to be deployed not only in drug discovery and development labs but now also in GMP-regulated manufacturing and quality... Read more


Charles River Laboratories to Present at Evercore Healthcare Conference

WILMINGTON, Mass. / Dec 01, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Evercore 8th Annual Healthcare Conference on Wednesday, December 3rd, at 10:00 a.m. ET. Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section... Read more


Kestra Medical Technologies Reports Preliminary Second Quarter Fiscal 2026 Financial Results

KIRKLAND, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported preliminary financial results for the second quarter fiscal 2026 ended October 31, 2025. “Revenue is expected to grow by over 50% in the second quarter and continues to exceed our FY26 plan, reflecting sustained commercial momentum as Kestra grows and penetrates the wearable defibrillator market,”... Read more


RadNet: DeepHealth Launches Breast Suite, Elevating Breast Cancer Detection, Risk Stratification and Workflow

Breast Suite is an industry-leading, comprehensive, and modular AI-powered suite of applications supporting more than 10 million mammograms annually delivering increased breast cancer detection rates,1 risk stratification tools, and viewing and reporting workflow acceleration CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), announced today the launch... Read more


BioNxt Solutions Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments

VANCOUVER, BC / ACCESS Newswire / December 1, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce it has signed a letter agreement with a European-based chemotherapy company (the "Codeveloper") for the exclusive intellectual property rights to a novel sublingual drug formulation using a high-potency active pharmaceutical ingredient for oncology... Read more


Kestra Medical Technologies Announces Primary Public Offering of Common Shares

KIRKLAND, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced an underwritten public offering of 5,500,000 common shares. Kestra is offering these shares pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (“SEC”). Kestra also intends to grant the underwriters a 30-day option to purchase up to an additional 825,000... Read more


Novocure Appoints Company President Frank Leonard as Chief Executive Officer

BAAR, Switzerland / Dec 01, 2025 / Business Wire / Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley Cordova who has resigned from the company. “During his more than 15-year career at Novocure, Frank has led many of our global business operations developing deep expertise in delivering our unique, device-based cancer... Read more


RadNet: DeepHealth Unveils Next-Generation Imaging Informatics and Clinical AI Solutions at RSNA 2025, Advancing a New Standard of AI-Powered Care

Company expands portfolio of novel AI-powered clinical and operational solutions delivering proven impact at scale—empowering breakthroughs in care through imaging CHICAGO, Nov. 30, 2025 (GLOBE NEWSWIRE) -- DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), today unveils an expanded portfolio at RSNA 2025, introducing next-generation imaging informatics and clinical AI solutions. The company... Read more


INVO Fertility Announces Intent to Acquire Indiana-Based Fertility Clinic “Family Beginnings”

Acquisition advances INVO’s national expansion strategy, enhances its clinical capabilities, and broadens access to innovative fertility care across the Midwest SARASOTA, Fla. and INDIANAPOLIS, Nov. 28, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced its... Read more


Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings

New BPH module and clinical data reinforce the TULSA Procedure™’s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today the... Read more


Avricore Health: HealthTab to Power NHS Pilot

Bringing Cholesterol-Lowering Injections to U.K. Community Pharmacies VANCOUVER, British Columbia, Nov. 27, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) is pleased to announce HealthTab™ is being deployed in a new pilot launched by Barts Health NHS Trust, in collaboration with UCL Partners and the British Heart Foundation (BHF), to deliver inclisiran cholesterol-lowering injections through community pharmacies. Key Hi... Read more


HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application

Company engaging in multiple options for a constructive resolution Strategy is underpinned by a clinical study that achieved the agreed upon endpoints Company believes that labeling modifications can address any outstanding concerns SANTA CLARA, Calif. / Nov 26, 2025 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced its regulatory strategy... Read more


Repligen to Present at Evercore Healthcare Conference

WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participate in the 8th Annual Evercore Healthcare Conference, being held December 2 -4 in Coral Gables, Florida. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on December 3rd at 1:20 p.m. ET. A live webcast of the conference presentations will... Read more


Picard Medical to Present the Next Generation Fully Implantable SynCardia Total Artificial Heart at ISMCS 2025

TUCSON, Ariz., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it will present in vitro data on the fully implantable Emperor Total Artificial Heart (TAH) at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support... Read more


Nyxoah’s Genio Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule

Assignment to New Technology APC 1580 is positive news for Nyxoah’s U.S. commercial rollout by strengthening hospital and ASC economics Mont-Saint-Guibert, Belgium – November 26, 2025, 7:45 am CET / 1:45 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Centers... Read more


Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

Actionable offering helps enable earlier, more personalized breast cancer interventions BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative bu... Read more


Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference

DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Wednesday, December 3, 2025, at 10:10 a.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the “Investors” section of the Company’s website... Read more


Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

Average Total Weight Loss of 23% With 14% Increase in Lean Body Mass After 12 Months All patients remained adherent to tirzepatide for the duration of the study NATICK, Mass. / Nov 25, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and... Read more


LivaNova to Present at Piper Sandler Healthcare Conference in December

LONDON / Nov 25, 2025 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City. The presentation will take place on Tues., Dec. 2, at 1:30 p.m. Eastern Standard Time. The discussion will be available to all interested parties who register to... Read more


VolitionRx Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use

HENDERSON, Nev., Nov. 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the first sale of its Nu.Q® Cancer assays to one of Europe's leading cancer centers, the Hospices Civils de Lyon, in Lyon, France. Professor Léa Payen, Professor in Toxicology and Biochemistry, Claude Bernard University of Lyon I and Hospices Civils de Lyon, France commented: "We are delighted to place this first... Read more


Owlet Partners With OpenSynergy to Power Next-Generation Bluetooth® Connectivity in Dream Sight Baby Monitor

Partnership underscores Owlet’s commitment to delivering trusted, seamless, and secure connected experiences for families worldwide. BERLIN & LEHI, Utah / Nov 25, 2025 / Business Wire / Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced that it selected OpenSynergy’s Blue SDK, an industry-leading independent Bluetooth® software stack, to deliver secure and reliable connectivity for its new Dream... Read more


Nano-X Imaging Engages with Althea France to Accelerate European Commercialization of Nanox.ARC System

Althea France, part of one of Europe's largest independent medical technology services providers, to distribute CE-marked Nanox.ARC system across French healthcare sector Partnership represents Nanox's fourth European distribution agreement following recent collaborations in Greece, Romania and Czech Republic PETACH TIKVA, ISRAEL – November 25, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical... Read more


New Clinical Evidence on Hologic’s AI-Powered Mammography Solutions Will Be Unveiled at RSNA

Studies demonstrate AI’s potential to streamline radiologists’ workflows while upholding high sensitivity in detecting cancer MARLBOROUGH, Mass. / Nov 25, 2025 / Business Wire / New data on Hologic’s (Nasdaq: HOLX) breast cancer detection technologies will be presented at the Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago, Illinois. “At Hologic, we’re committed to advancing our technologies to support... Read more


BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company’s Growth Strategy and Deep TMS™ Treatment December 1, 2025

BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that it will host a virtual Analyst & Investor Day on Monday, December 1, 2025 at 10:00 AM ET, during which company management will highlight various aspects of BrainsWay’s growth strategy. The event will feature Owen Scott Muir, MD,... Read more


AVITA Medical to Present at the Piper Sandler 37ᵗʰ Annual Healthcare Conference

VALENCIA, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025, at 8:30 a.m. EST. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference. A live audio webcast... Read more


Agilent Technologies Reports Fourth-Quarter Fiscal Year 2025 Financial Results

Delivers solid results in Q4, initiates FY26 guidance Fourth-quarter fiscal year 2025 Revenue of $1.86 billion for the fourth quarter ended October 31, 2025, exceeding revenue guidance and representing growth of 9.4% reported and up 7.2% on a core(1) basis compared with the fourth quarter of 2024. GAAP net income of $434 million; earnings per share (EPS) of $1.53, up 25% from the fourth quarter of 2024. Non-GAAP(2) net income of $452 million; EPS of $1.59, up 9% from... Read more


CareDx: SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation

Third SHORE Publication Highlights HeartCare’s Role in Risk Stratification and Personalized Post-Transplant Care SOUTH SAN FRANCISCO, Calif. / Nov 24, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication of the third manuscript from... Read more


Hinge Health Reduces MRIs and X-Rays for Back Pain by 60%

SAN FRANCISCO / Nov 24, 2025 / Business Wire / Hinge Health, Inc. (NYSE: HNGE) today announced a new study showing that participants in its chronic back pain program had substantially fewer imaging visits, such as X-rays and MRIs, compared to a similar group of individuals who sought traditional PT care. The peer-reviewed study, published in The Journal of Health Economics and Outcomes Research found that of the 4,330 participants, those who used Hinge Health had 60% fewer... Read more


LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services

New patient implants assigned to New Technology Ambulatory Payment Classification 1580 End-of-service procedures elevated to Level 5 APC Effective Jan. 1, 2026, will improve economics for hospitals performing Medicare procedures and significantly reduces a known barrier to procedure penetration LONDON / Nov 24, 2025 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the U.S. Centers for Medicare & Medicaid... Read more


Lantheus to Present Florbetaben F 18 Data at CTAD 2025

BEDFORD, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new florbetaben F18 data at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) 2025 conference, taking place December 1-4, in San Diego, CA. Presentation details are as follows: Poster... Read more


DarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year

Sanofi and Symphony Health teams conducted the study demonstrating how Dario's digital, diabetes intervention platform reduces real-world healthcare burden and cost compared to usual care Representing a high-rigor, real world analysis, the study found Dario users, as compared to matched individuals receiving usual care, had 23% lower hospitalization rates and 26% lower all-cause charges More frequent engagement on the Dario platform associated with fewer inpatient and... Read more


Sera Prognostics Announces Publication Acceptance for PRIME Study

The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year SALT LAKE CITY, Nov. 24, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the findings of the Prematurity Risk Assessment... Read more


NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services

Physician Fee Schedule (PFS) final rule substantially increases reimbursement for RNS neurostimulator implantation and replacement procedures CY 2026 Outpatient Prospective Payment System (OPPS) Final Rule moves RNS replacement procedures to highest-paying neurostimulator APC MOUNTAIN VIEW, Calif. / Nov 24, 2025 / Business Wire / NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today announced... Read more


Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates

Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and treatment of non-convulsive seizures SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug A... Read more


InspireMD: Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

Carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis MIAMI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, welcomes the recent presentation and publication of CREST-2 data which demonstrated... Read more


Becton Dickinson Surgiphor™ Surgical Wound Irrigation System Expands to Europe to Help Hospitals Improve Patient Safety

FRANKLIN LAKES, N.J., Nov. 24, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD Surgiphor™ Surgical Wound Irrigation System in Europe. The system is the first of its kind to receive Conformité Européenne (CE) approval and is now available in select European countries. BD Surgiphor™ is a sterile, ready-to-use irrigation solution designed to help loosen and remove... Read more


Nano-X Imaging Announces $15 Million Registered Direct Offering of Common Stock

PETACH TIKVA, Israel, Nov. 23, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,826,530 ordinary shares (“Common Stock”) in a registered direct offering. The offering is expected to result in gross proceeds of approximately $15 million,... Read more


Theralase Technologies Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

Toronto, Ontario--(Newsfile Corp. - November 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC") as the sole agent and bookrunner on a commercially reasonable "best... Read more


Labcorp Appoints Victor Bulto to Board of Directors

Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1,... Read more


Nanalysis Scientific Announces Third Quarter 2025 Results

CALGARY, AB, Nov. 24, 2025 /CNW/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR spectrometers and MRI technology for industrial and research applications, announces third quarter results for the period ending on September 30, 2025. Chief Executive Officer Sean Krakiwsky and Chief Financial Officer Randall McRae will host a conference call at 4:15 P.M. Eastern Time t... Read more


New Data at the Asia Pacific Heart Rhythm Society (APHRS) 2025 Highlight the Performance of iRhythm’s Zio Long-Term Continuous Monitoring in an Asian Population

iRhythm Technologies presented new data during the joint Asia Pacific Heart Rhythm Society (APHRS) and Japan Heart Rhythm Society (JHRS) scientific sessions. Large-scale analysis of more than 400,000 patients1 supports the consistency and generalizability of Zio long-term ECG monitoring (LTCM) performance across populations; median wear and analyzable time among patients identified as Asian (3.4% of the cohort) were comparable to those of non-Asian patients, and findings... Read more


Azenta Reports Fourth Quarter and Full Year Fiscal 2025 Results, Ended September 30, 2025

Q4'25 reported revenue growth of 6% year over year and 4% on an organic basis FY'25 reported revenue growth of 4% and 3% on an organic basis FY'25 Adjusted EBITDA margin expansion of 310 basis points versus last year FY'26 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis points BURLINGTON, Mass., Nov. 21, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results... Read more


Conavi Medical Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

PRELIMINARY PROSPECTUS ACCESSIBLE ON SEDAR+ TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, announced today that it has filed a preliminary short form prospectus (the “Preliminary Prospectus”) with the securities regulatory... Read more



RxSight to Present at the Piper Sandler Healthcare Conference

ALISO VIEJO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) – November 20, 2025 -- RxSight, Inc. (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Piper Sandler 37th Annual Healthcare Conference in New York City. RxSight’s management is scheduled to present on Wednesday, December 3, 2025, at 12:00 p.m. Eastern Time.... Read more


PROCEPT BioRobotics to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025

SAN JOSE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 37th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Tuesday, December 2 at 8:30 a.m. Eastern Time. A live webcast of each event,... Read more


SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference

DENVER, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education... Read more


New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Technologies Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention...

Case-controlled study in 1,143 patients demonstrates superior weight reduction, fat mass loss, and visceral fat loss with the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle intervention alone Average weight reduction of 20% at 36 weeks, on par with bariatric surgery and high-dose GLP-1 therapy Improved body composition without adversely affecting muscle mass NATICK, Mass. / Nov 20, 2025 / Business Wire / Allurion Technologies, Inc.... Read more


Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health

SALT LAKE CITY, Nov. 20, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company's Executive Vice President of Business Development, Joseph Featherstone, addressed a satellite session of the International Union Against Tuberculosis and Lung Disease (The Union) 2025 World Conference on Lung Health... Read more


DexCom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States

Designed to provide real-time glucose readings for an industry-leading 15.5 days*†, Dexcom G7 15 Day will be available in the U.S. for people over the age of 18 with diabetes beginning on Dec. 1, 2025. Dexcom G7 15 Day will first be available through durable medical equipment (DME) providers with full retail launch in the coming weeks. Dexcom CGM continues to be the most covered and reimbursed CGM brand on the market1. SAN DIEGO / Nov 20, 2025 / Business Wire / DexCom,... Read more